256 related articles for article (PubMed ID: 21427071)
1. Outcome of idiopathic membranous nephropathy using targeted stepwise immunosuppressive treatment strategy.
Aaltonen S; Honkanen E
Nephrol Dial Transplant; 2011 Sep; 26(9):2871-7. PubMed ID: 21427071
[TBL] [Abstract][Full Text] [Related]
2. Outcome of Idiopathic Membranous Nephropathy: A Retrospective Study.
Rozenberg I; Kotliroff A; Zahavi T; Benchetrit S
Isr Med Assoc J; 2018 Mar; 20(3):186-189. PubMed ID: 29527859
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological Features of Idiopathic Membranous Nephropathy in 33 Adolescents.
Li C; Li H; Wen YB; Li JN; Lin WF; Cai JF; Duan L; Li Y; Li XM; Li XW
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Aug; 39(4):544-551. PubMed ID: 28877834
[TBL] [Abstract][Full Text] [Related]
4. Idiopathic membranous nephropathy in pediatric patients: presentation, response to therapy, and long-term outcome.
Chen A; Frank R; Vento S; Crosby V; Chandra M; Gauthier B; Valderrama E; Trachtman H
BMC Nephrol; 2007 Aug; 8():11. PubMed ID: 17683621
[TBL] [Abstract][Full Text] [Related]
5. Short- and long-term efficacy of oral cyclophosphamide and steroids in patients with membranous nephropathy and renal insufficiency. Study Group.
Branten AJ; Wetzels JF
Clin Nephrol; 2001 Jul; 56(1):1-9. PubMed ID: 11499653
[TBL] [Abstract][Full Text] [Related]
6. Early initiation of immunosuppressive treatment in membranous nephropathy patients.
Chan CK; Lai TS; Chen PM; Chou YH; Wu CF; Chiu YL; Chiang WC; Chen YM; Chu TS; Wu KD
J Formos Med Assoc; 2017 Apr; 116(4):266-275. PubMed ID: 28202222
[TBL] [Abstract][Full Text] [Related]
7. Introduction of a cyclophosphamide-based treatment strategy and the risk of ESRD in patients with idiopathic membranous nephropathy: a nationwide survey in the Netherlands.
Hofstra JM; Wetzels JF
Nephrol Dial Transplant; 2008 Nov; 23(11):3534-8. PubMed ID: 18559961
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of a second course of immunosuppressive therapy in patients with membranous nephropathy and persistent or relapsing disease activity.
du Buf-Vereijken PW; Wetzels JF
Nephrol Dial Transplant; 2004 Aug; 19(8):2036-43. PubMed ID: 15187191
[TBL] [Abstract][Full Text] [Related]
9. Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy: a randomized controlled trial.
Hofstra JM; Branten AJ; Wirtz JJ; Noordzij TC; du Buf-Vereijken PW; Wetzels JF
Nephrol Dial Transplant; 2010 Jan; 25(1):129-36. PubMed ID: 19666912
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate.
du Buf-Vereijken PW; Branten AJ; Wetzels JF;
Nephrol Dial Transplant; 2004 May; 19(5):1142-8. PubMed ID: 14993502
[TBL] [Abstract][Full Text] [Related]
11. A 10-year follow-up of idiopathic membranous nephropathy patients on steroids and cyclophosphamide: a case series.
Ram R; Guditi S; Kaligotla Venkata D
Ren Fail; 2015 Apr; 37(3):452-5. PubMed ID: 25594615
[TBL] [Abstract][Full Text] [Related]
12. Restrictive use of immunosuppressive treatment in patients with idiopathic membranous nephropathy: high renal survival in a large patient cohort.
du Buf-Vereijken PW; Feith GW; Hollander D; Gerlag PG; Wirtz JJ; Noordzij TC; Wetzels JF;
QJM; 2004 Jun; 97(6):353-60. PubMed ID: 15152109
[TBL] [Abstract][Full Text] [Related]
13. Urinary N-acetyl-β-glucosaminidase and estimated Glomerular filtration rate may identify patients to be treated with immuno-suppression at diagnosis in idiopathic membranous nephropathy.
Bazzi C; Usui T; Rizza V; Casellato D; Gallieni M; Nangaku M
Nephrology (Carlton); 2018 Feb; 23(2):175-182. PubMed ID: 27764902
[TBL] [Abstract][Full Text] [Related]
14. Risk of infection with different immunosuppressive drugs combined with glucocorticoids for the treatment of idiopathic membranous nephropathy: A pairwise and network meta-analysis.
Liu D; Yang Y; Kuang F; Qing S; Hu B; Yu X
Int Immunopharmacol; 2019 May; 70():354-361. PubMed ID: 30852290
[TBL] [Abstract][Full Text] [Related]
15. Cyclosporin A treatment for idiopathic membranous nephropathy.
Yao X; Chen H; Wang Q; Tang Z; Hu W; Yin G; Liu Z; Li L
Chin Med J (Engl); 2001 Dec; 114(12):1305-8. PubMed ID: 11793859
[TBL] [Abstract][Full Text] [Related]
16. Comparison of different therapies in high-risk patients with idiopathic membranous nephropathy.
Peng L; Wei SY; Li LT; He YX; Li B
J Formos Med Assoc; 2016 Jan; 115(1):11-8. PubMed ID: 26315481
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological features and outcome in elderly patients with idiopathic membranous nephropathy.
Liang J; Hao W; Xia F; Zhao Z; Wu Y; Yu F; Hu W; Fang X; Liu W
Ren Fail; 2023 Dec; 45(1):2212081. PubMed ID: 37194712
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness and tolerance of immunosuppressive treatments for idiopathic membranous nephropathy: A network meta-analysis.
Ren S; Wang Y; Xian L; Toyama T; Jardine M; Li G; Perkovic V; Hong D
PLoS One; 2017; 12(9):e0184398. PubMed ID: 28898290
[TBL] [Abstract][Full Text] [Related]
19. Response to immunosuppressive therapy in PLA
Wang J; Xie Q; Sun Z; Xu N; Li Y; Wang L; Liu S; Xue J; Hao CM
BMC Nephrol; 2017 Jul; 18(1):227. PubMed ID: 28693446
[TBL] [Abstract][Full Text] [Related]
20. Renal outcomes of idiopathic and atypical membranous nephropathy in adult Chinese patients: a single center retrospective cohort study.
Jiang Z; Cai M; Dong B; Yan Y; Wang Y; Li X; Shao C; Zuo L
BMC Nephrol; 2021 Apr; 22(1):148. PubMed ID: 33888083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
